Company Overview and News

 
FBM KLCI up 0.47% after Hong Leong Bank, MISC spike

2018-10-16 theedgemarkets
KUALA LUMPUR (Oct 16): The FBM KLCI gained 8.1 points or 0.47% to close at its intraday high after a sudden surge in the final trading hour. At a glance, the KLCI surged as prices of index-linked stocks Hong Leong Bank Bhd and MISC Bhd spiked.
3026 5819 2836

 
KLCI rises 0.24% as blue chips lift

2018-10-15 theedgemarkets
KUALA LUMPUR (Oct 15): The FBM KLCI rose 0.24% at mid-morning today, defending its level above the 1,730-point level, lifted by gains at select blue chips.
HLFBF 7293 BRDBF MLYNF 7113 TPGVF 2089 5199 5210 3026 2836 HIPEF GEBHF HRGHY 5183 MLYBY PECGF UPBMF 1082 5681 5168 TGLVY 5436 5238 1155 0047

 
KLCI starts lower in line with frail regional markets

2018-10-12 theedgemarkets
KUALA LUMPUR (Oct 12): The FBM KLCI fell for the eighth day running this morning, amid frail regional sentiment.
HLFBF 3026 PBLOF 3867 5819 1082 1295 BSMAF 3034 7022 GBTKF 1818

 
KLCI remains marginally lower, construction stocks fall

2018-10-08 theedgemarkets
KUALA LUMPUR (Oct 8): The FBM KLCI remained marginally in the negative zone, having pared much of its losses in the morning session today, against the backdrop of weaker regional markets.
SPMXF 7036 5681 5263 BATS 4162 1163 5256 7123 5199 SPMXY 5225 3026 3301 3867 1899 Q0F IHHHF HIPEF GEBHF

 
KLCI pares loss, remains in red tracking regional markets

2018-10-08 theedgemarkets
KUALA LUMPUR (Oct 8): The FBM KLCI pared some of its loss at mid-morning today, but remained in the negative zone in line with its key regional peers.
HLFBF SPMXF UPBMF 7036 1082 7113 TPGVF BATS 4162 7087 2089 9334 7123 TGLVY SPMXY 5225 3026 3301 0026 1899 Q0F IHHHF GEBHF

 
KLCI remains in the red, tracks regional slump

2018-10-04 theedgemarkets
KUALA LUMPUR (Oct 4): The FBM KLCI retreated at the midday break, in line with slump at most regional markets.
HLFBF 5183 PECGF 1082 BATS 4162 7765 5014 9334 7123 5199 4588 3026 0026 5219 MYPRY HIPEF

 
KLCI down 0.36% on sustained weaker sentiment

2018-10-04 theedgemarkets
KUALA LUMPUR (Oct 4): The FBM KLCI retreated at mid-morning today on sustained weaker sentiment at the domestic market.
7083 5183 5172 PECGF BATS 4162 5014 5199 4634 KLKBY 2445 5226 4456 5347 3026 0026 TNABY MYPRY 2836 TNABF HIPEF

 
KLCI stays shy of 1,800 as regional markets retreat

2018-10-02 theedgemarkets
KUALA LUMPUR (Oct 2): The FBM KLCI was hard pressed to find a firm footing in the morning session and remained below the crucial 1,800-point level at the midday break, as regional markets retreated.
HLFBF BRDBF UPBMF 1082 5168 2089 5256 5255 9334 5199 5210 4634 5139 4456 3026 0900 0026 7108 2836 HIPEF GEBHF HRGHY

 
FBM KLCI pares gains, subdued in line with region

2018-10-01 theedgemarkets
KUALA LUMPUR (Oct 1): The FBM KLCI pared some of its gains at mid-morning, keeping the local index subdued in line with the regional markets on the first trading day of the fourth quarter.
APEXF 7090 BATS 4162 2089 5256 9334 5199 5008 5843 1201 3026 3301 3867 2836 HIPEF PNAGF 7084 UPBMF 5681 5268 6033 PNADF 0026 1899

 
KLCI claws back to erase loss, Tenaga lifts

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): The FBM KLCI clawed back to erase its earlier losses at the midday break today, powered by gains at Tenaga Nasional Bhd and other select index-linked blue chips.
7084 7060 7036 0083 BATS 4162 7765 1163 5256 9334 5199 0154 KLKBY 5029 2445 5347 5258 3026 7216 TNABY 2836 TNABF HIPEF 1929

 
KLCI pares loss, sentiment stays tepid

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): The FBM KLCI pared some of its losses at mid-morning today as the local index tracked regional markets.
HLFBF 5183 PECGF 7060 8621 7036 1082 BATS 4162 5256 5199 7233 5347 3026 TNABY 2836 TNABF HIPEF 1929

 
KLCI falls 0.57% as China calls off trade talks with US

2018-09-24 theedgemarkets
KUALA LUMPUR (Sept 24): The FBM KLCI fell 0.57% at the midday breakin line with the tumble at most regional markets after China called off the trade talks with US officials.
APEXF 7090 UPBMF 5031 5202 2089 9334 6033 7123 5199 KLKBY 2445 PNADF 5347 3026 3867 0026 TNABY 5819 2836 1902 TNABF HIPEF PNAGF

 
KLCI slips 0.19% on mild profit taking

2018-09-24 theedgemarkets
KUALA LUMPUR (Sept 24): The FBM KLCI slipped at mid-morning and dipped 0.19% on some mild profit taking.
7052 7060 UPBMF 7036 5202 2089 6033 7123 5199 PNADF 3026 3867 0026 6645 5819 2836 1902 HIPEF PNAGF

 
KLCI pares gains, stays up 0.28%

2018-09-20 theedgemarkets
KUALA LUMPUR (Sept 20): The FBM KLCI pared some of its gains and was up 0.28% at midday break, while remaining above the crucial 1,800-point level, in line with the advance at most regional markets.
HLFBF APEXF 7052 5183 7090 GMALF PECGF 1082 2291 0096 5256 9334 5134 7277 5199 GMALY 5436 4588 3026 4715 5819 2836 HIPEF

 
KLCI up 0.53%, stays above 1,800-level

2018-09-19 theedgemarkets
KUALA LUMPUR (Sept 19): The FBM KLCI rose 0.53% at midday break today, tracking the broad-based uptrend at regional markets, while staying above the crucial 1,800-point level.
HLFBF 7052 PBLOF 7060 8621 1082 7113 TPGVF BATS 4162 1163 1295 6033 5199 TGLVY 4588 PNADF 3026 0026 5819 HIPEF PNAGF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...